Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis
Koki Tsuchiya,1 Koji Ishikawa,1 Soji Tani,1 Yusuke Oshita,2 Takuma Kuroda,1 Ryo Yamamura,1 Haruka Emori,1 Hiroshi Maruyama,1 Akira Matsuoka,1 Yoshifumi Kudo,1 Toshiyuki Shirahata,1 Tomoaki Toyone,1 Takashi Nagai,1 Katsunori Inagaki11Department of Orthopaedic Surgery, Showa University School of Medic...
Main Authors: | Tsuchiya K, Ishikawa K, Tani S, Oshita Y, Kuroda T, Yamamura R, Emori H, Maruyama H, Matsuoka A, Kudo Y, Shirahata T, Toyone T, Nagai T, Inagaki K |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-08-01
|
Series: | Clinical Interventions in Aging |
Subjects: | |
Online Access: | https://www.dovepress.com/analysis-of-three-dimensional-bone-mineral-density-and-bone-strength-m-peer-reviewed-article-CIA |
Similar Items
-
High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
by: Ishikawa K, et al.
Published: (2016-12-01) -
High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
by: Ishikawa K, et al.
Published: (2018-10-01) -
Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment
by: Nakamura Y, et al.
Published: (2017-10-01) -
Effect of risedronate on bone loss at discontinuation of denosumab
by: Michel Laroche, et al.
Published: (2020-12-01) -
Pre-treatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
by: Kamimura M, et al.
Published: (2018-04-01)